1.38
price down icon2.13%   -0.03
after-market Handel nachbörslich: 1.40 0.02 +1.45%
loading

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

pulisher
10:14 AM

Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in

10:14 AM
pulisher
06:49 AM

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st

06:49 AM
pulisher
Oct 01, 2025

Is Lexicon Pharmaceuticals Inc. stock bottoming outJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIJuly 2025 Fed Impact & Daily Growth Stock Tips - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Weekly Trend Report & AI Driven Stock Price Forecasts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Is Lexicon Pharmaceuticals Inc. a candidate for recovery playAnalyst Downgrade & Long Hold Capital Preservation Tips - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price action2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in

Sep 28, 2025
pulisher
Sep 26, 2025

Lexicon reports FDA's decision to extend review period for Zynquista - MSN

Sep 26, 2025
pulisher
Sep 24, 2025

Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener

Sep 23, 2025
pulisher
Sep 23, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon pharmaceuticals announces update on submission of additional data to U.S. FDA - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon expects delay in FDA feedback on additional data for its diabetes drug - Reuters

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon (LXRX) Seeks FDA Feedback on Zynquista with New Data Sub - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon Pharmaceuticals Provides Update on Zynquista NDA Resubmission Following FDA Feedback - Quiver Quantitative

Sep 22, 2025
pulisher
Sep 22, 2025

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

FDA Extends Review of Breakthrough Diabetes Drug Zynquista: What Lexicon's New Data Shows - Stock Titan

Sep 22, 2025
pulisher
Sep 20, 2025

Nasdaq Moves: Whats the MACD signal for Lexicon Pharmaceuticals IncStop Loss & Verified High Yield Trade Plans - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat

Sep 20, 2025
pulisher
Sep 20, 2025

Market Review: What is the target price for Lexicon Pharmaceuticals Inc stockM&A Rumor & Entry Point Strategy Guides - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Guidance Update: Can Lexicon Pharmaceuticals Inc. reach all time highs this yearMarket Performance Summary & Daily Technical Forecast Reports - خودرو بانک

Sep 20, 2025
pulisher
Sep 19, 2025

Geopolitics Watch: Is Lexicon Pharmaceuticals Inc a defensive stockPortfolio Gains Report & Risk Controlled Swing Alerts - خودرو بانک

Sep 19, 2025
pulisher
Sep 18, 2025

What makes Lexicon Pharmaceuticals Inc. stock attractive todayWeekly Trend Recap & Reliable Intraday Trade Alerts - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

CEO Moves: What is Lexicon Pharmaceuticals Incs valuation compared to sectorEntry Point & Reliable Volume Spike Alerts - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

How volatile is Lexicon Pharmaceuticals Inc. stock2025 Market WrapUp & Weekly Return Optimization Alerts - خودرو بانک

Sep 18, 2025
pulisher
Sep 17, 2025

Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Stu - GuruFocus

Sep 17, 2025
pulisher
Sep 17, 2025

Lexicon Pharmaceuticals Presents Promising Phase 2b Results for Pilavapadin in Treating Diabetic Peripheral Neuropathic Pain - Quiver Quantitative

Sep 17, 2025
pulisher
Sep 17, 2025

2-Point Pain Reduction: Lexicon's Non-Opioid Drug Could Be First New DPNP Treatment in 20 Years - Stock Titan

Sep 17, 2025
pulisher
Sep 17, 2025

Lexicon Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com

Sep 17, 2025
pulisher
Sep 16, 2025

Is Vistagen Therapeutics Inc. forming a bullish divergenceTake Profit & Comprehensive Market Scan Reports - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Breakouts Watch: Whats the MACD signal for Lexicon Pharmaceuticals IncJuly 2025 Short Interest & Free Risk Controlled Daily Trade Plans - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Aug Update: What’s the MACD signal for NHPAPEarnings Growth Report & AI Driven Stock Price Forecasts - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Lexicon Pharmaceuticals jumps amid takeover speculation - MSN

Sep 16, 2025
pulisher
Sep 16, 2025

Market Outlook: What’s the RSI of Lexicon Pharmaceuticals Inc. stockRecession Risk & Real-Time Volume Triggers - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Panic Selling: What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)2025 Macro Impact & Weekly Market Pulse Updates - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Market Review: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaIPO Watch & Pattern Based Trade Signal System - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Wall Street Recap: What is Kaltura Inc. s debt to equity ratioJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Published on: 2025-09-16 15:08:33 - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Buybacks Report: What drives Lexicon Pharmaceuticals Incs stock pricePortfolio Performance Summary & Safe Capital Growth Trade Ideas - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Performance Recap: Will Lexicon Pharmaceuticals Inc benefit from sector rotationQuarterly Trade Report & Long-Term Capital Growth Ideas - خودرو بانک

Sep 16, 2025
pulisher
Sep 15, 2025

Aug Movers: What is the target price for Lexicon Pharmaceuticals Inc stockTrade Risk Assessment & Technical Pattern Based Buy Signals - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

Institution Moves: Is Lexicon Pharmaceuticals Inc stock trending bullish2025 Momentum Check & Community Shared Stock Ideas - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

MACD Signal: Should I hold or sell Lexicon Pharmaceuticals Inc now2025 Historical Comparison & AI Forecast Swing Trade Picks - خودرو بانک

Sep 15, 2025
pulisher
Sep 11, 2025

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - The Manila Times

Sep 11, 2025
pulisher
Sep 11, 2025

Lexicon Pharmaceuticals Presents Promising Data on Pilavapadin for Diabetic Peripheral Neuropathic Pain at Upcoming Medical Meetings - Quiver Quantitative

Sep 11, 2025
pulisher
Sep 11, 2025

Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com

Sep 11, 2025
pulisher
Sep 11, 2025

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming ... - nrtoday.com

Sep 11, 2025
pulisher
Sep 11, 2025

Novel Non-Opioid Pain Drug Data: Lexicon's Pilavapadin Shows Promise for Diabetic Neuropathy Treatment - Stock Titan

Sep 11, 2025
pulisher
Sep 11, 2025

Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada

Sep 11, 2025
$36.49
price up icon 0.47%
$86.28
price down icon 0.48%
$32.12
price up icon 1.10%
$104.51
price up icon 2.25%
$152.80
price up icon 3.75%
biotechnology ONC
$345.17
price up icon 2.99%
Kapitalisierung:     |  Volumen (24h):